Bristol-Myers Squibb has patented a pharmaceutical composition containing antibodies that bind to human CD40 without activating it. The antibodies may have a modified IgG1 Fc domain and are useful in treating diseases involving CD40 activity. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Bristol-Myers Squibb Co - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of February 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Humanized antibodies binding cd40 for treatment of cd40-related diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Bristol-Myers Squibb Co

A recently granted patent (Publication Number: US11926673B2) discloses a pharmaceutical composition that includes an antibody or antigen binding portion specifically targeting human CD40, along with a pharmaceutically acceptable carrier. The antibody structure consists of a first polypeptide portion containing a heavy chain variable region and a human heavy chain constant region, and a second polypeptide portion comprising a light chain variable region and a human light chain constant region. Notably, the heavy chain variable region includes specific sequences (CDR1, CDR2, and CDR3) and the light chain variable region also contains distinct sequences (CDR1, CDR2, and CDR3).

Furthermore, the patent details various configurations and mutations within the antibody structure, such as alterations in the human heavy chain constant region to reduce binding to specific receptors. The composition also encompasses different amino acid sequences for the heavy and light chain variable regions, along with options for humanization and linkage to therapeutic agents or additional functional moieties. The patent covers a range of possibilities for the antibody or antigen binding portion, including single-chain variable fragments (scFv-Fc) and the inclusion of extra moieties for enhanced functionality.

To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies